A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...
Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...
The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.
Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor ...
Hosted on MSN
How Proteins Are Made: From DNA to Function
Proteins are essential biological molecules that perform a vast array of functions crucial for life, from catalyzing biochemical reactions and transporting molecules to providing structural support ...
InvestorsHub on MSN
Akari Therapeutics shares climb after encouraging early data for pancreatic cancer candidate
Akari Therapeutics PLC (NASDAQ:AKTX) saw its stock rise 7.9% in premarket trading on Tuesday after unveiling new preclinical ...
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical ...
The first 100 bases of many genes show excess mutations, revealing a major genomic weak spot that shapes disease risk and ...
Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback